Sun Pharma announces successful completion of Opiates business acquisition in Australia

Sun Pharma announces successful completion of Opiates business acquisition in Australia


·        Significantly expands NRM capability through two Opiates manufacturing facilities in Australia

·        Strengthens Sun Pharma's strategic position in Global opiates market

MUMBAI, September 1, 2015 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715), today begins the integration of its Opiates business in Australia following the successful completion of this acquisition from GSK (announced in March 2015).  This acquisition fortifies Sun Pharma's global position with two Opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally. 

Sun Pharma now offers a rich basket of Opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialized team to drive business growth. 

The Opiates acquisition allows Sun Pharma to: 
·        Significantly expands its narcotics raw material (NRM) market share.

·        Enhance Opiate Alkaloids portfolio and depth in Global opiates market.

·        Strengthen its strategic position in the global Opiates business.

Welcoming the Opiates team in Australia, Mr Anil Kumar Jain, CEO – API Business, Sun Pharma said, "The successful completion of this acquisition enables us to leverage our unique position in the global Opiates business by capitalizing our global footprint and global ranking in the specialty generics market. Sun Pharma stays committed to uncompromised product quality, 100% compliance and innovation." 

Over the last few months, the Opiates & Sun Pharma teams put together a transition plan to oversee the implementation of the functional integration of Opiates business. The transition process will emphasize on aligning best functional requirements and leveraging employee talents in this business.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 45 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 13 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 11 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues. For further information please visit www.sunpharma.com or Follow us on Twitter @SunPharma_Live 

FOR FURTHER INFORMATION PLEASE CONTACT:

Frederick Castro

Tel +91 22 4324 4324, Xtn 2777

Tel Direct +91 22 4324 2777

Mobile +91 99206 65176

E mail [email protected]

Nimish Desai

Tel +91 22 4324 4324, Xtn 2778

Tel Direct +91 22 4324 2778

Mobile +91-98203 30182

E mail [email protected]

 

 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.